Phase 2 N=72 A Study of Pemetrexed in Children With Recurrent Cancer
Osteosarcoma · Medulloblastoma · Sarcoma, Ewing's
Primary: Percentage of Participants With Overall Tumor Response (Response Rate) — 0; 0; 0; 0 Percentage of Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=642 Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma
Localized Extraskeletal Ewing Sarcoma · Peripheral Primitive Neuroectodermal Tumor of Bone · Peripheral Primitive Neuroectodermal Tumor of Soft Tissues
Primary: Event-Free Survival — 77.64; 78.79 Percent Probability
Phase 2 N=44 Therapy to Treat Ewing's Sarcoma, Rhabdomyosarcoma or Neuroblastoma
Neuroblastoma · Sarcoma · Rhabdomyosarcoma-Embryonal
Primary: Number of Participants With a Positive Immune Response as Evidenced by the Delayed Type of Hypersensitivity (DTH) Reaction Assay — 0; 15 Participants — p=0.043
N/A N=35 Two Regimens of Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed Localized Ewing Sarcoma Family of Tumors
Ewing Sarcoma of Bone · Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
Primary: Incidence of Death — 0 participants
Phase 2 N=50 Trabectedin in Treating Young Patients With Recurrent or Refractory Soft Tissue Sarcoma or Ewing's Family of Tumors
Previously Treated Childhood Rhabdomyosarcoma · Recurrent Childhood Rhabdomyosarcoma · Recurrent Childhood Soft Tissue Sarcoma
Primary: Response (Complete Response [CR] and Partial Response [PR]) — 1; 0; 0; 0 participants
Phase 1 N=65 Study Of Anti-IGF-IR CP-751,871 In Patients With Solid Tumors
Sarcoma, Ewing's
Primary: Number of Participants With Treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 3; 3; 3; 3 participants
Phase 2 N=10 Study Of CP-751,871 In Patients With Ewing's Sarcoma Family Of Tumors
Ewing's Sarcoma Family of Tumors
Primary: Objective Response Rate (ORR) — 14.2 percentage of participants
Phase 2 N=13 Antineoplaston Therapy in Treating Children With Primitive Neuroectodermal Tumors
Childhood CNS Primitive Neuroectodermal Tumor
Primary: Number of Participants With Objective Response — 3; 1; 1; 7 Participants
Phase 3 N=91 Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma
Anaplastic Medulloblastoma · Medulloblastoma · Supratentorial Embryonal Tumor, Not Otherwise Specified
Primary: Number of Patients Who Have Either a Complete Response (CR) Rate or No Complete Response Rate — 13; 15; 16; 15 Participants — p=0.35
Phase 2 N=10 Cytarabine in Treating Young Patients With Recurrent or Refractory Ewing's Sarcoma
Sarcoma
Primary: Response — 10; 0 participants
Phase 2 N=48 Combination Chemotherapy in Treating Patients With Stage III or Stage IV Malignant Peripheral Nerve Sheath Tumors
Neurofibromatosis Type 1 · Sarcoma
Primary: Number of Participants With Response Rate (Complete Response and Partial Response) — 5; 4; 0; 0 Participants
Phase 2 N=7 Vincristine Sulfate, Topotecan Hydrochloride, and Cyclophosphamide With or Without Bevacizumab in Treating Young Patients With Refractory or First Recurrent Extracranial Ewing Sarcoma
Ewing Sarcoma of Bone · Extraosseous Ewing Sarcoma · Peripheral Primitive Neuroectodermal Tumor
Primary: The Occurrence of Limiting Toxicity in an Eligible and Evaluable Patient. — 0 number of toxicities
Phase 2 N=12 Olaparib in Adults With Recurrent/Metastatic Ewing's Sarcoma
Ewing's Sarcoma
Primary: Objective Response Rate of Olaparib — 0 Participants
Phase 2 N=20 S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
Sarcoma
Primary: Patients With Response (Confirmed Complete, and Partial) With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor When Treated With Erlotinib. — 0…
Phase 2 N=10 Busulfan, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk Ewing's Tumors
Sarcoma
Primary: Overall Objective Response — 4; 1 participants
Phase 2 N=17 Study of Zalypsis® (PM00104) in Patients With Unresectable Locally Advanced and/or Metastatic Ewing Family of Tumors (EFT) Progressing After at Least One Prior Line of Chemotherapy
Ewing's Sarcoma · Primitive Neuroectodermal Tumor (PNET) · Askin's Tumor of the Chest Wall
Primary: Overall Response Rate (ORR) — 0 Participants
Phase 2 N=9 Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing's Sarcoma and Neuroblastoma
Neuroblastoma · Sarcoma
Primary: Objective Response Rate
Phase 2 N=60 Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas
Sarcoma
Primary: Number of Participants With Engraftment — 23 Participants
Phase 2 N=38 Vinblastine, Celecoxib, and Combination Chemotherapy in Treating Patients With Newly-Diagnosed Metastatic Ewing's Sarcoma Family of Tumors
Sarcoma
Primary: Occurrence of Severe Toxicity — 1; 1 participants
Phase 2 N=21 Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Participants With Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) and Ewing Sarcoma (EWS)
Relapsed/Refractory Rhabdomyosarcoma · Non-rhabdomyosarcoma Soft Tissue Sarcoma · Ewing Sarcoma
Primary: Percentage of Participants With Objective Response — 0; 0; 0 percentage of participants
Phase 3 N=413 Treatment of Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor
Brain and Central Nervous System Tumors
Primary: Progression-Free Survival (PFS) in ERBB2-Negative Tumors Compared to ERBB2-Positive Tumors — 79.2; 83.3; 69.6; 86.7 probability of PFS at 2 years — p=0.8001
Phase 3 N=588 Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma
Adult Alveolar Soft-part Sarcoma · Adult Angiosarcoma · Adult Epithelioid Sarcoma
Primary: Probability for Event Free Survival. — 0.8984; 0.7647; 0.6079; 0.4873 Probability of EFS at 5 years
Phase 2 N=13 Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Sarcoma
Sarcoma
Primary: Number of Participants With Grade 3 Bilirubin — 3 participants with Grade 3 Bilirubin
Phase 2 N=13 Protracted Etoposide During Induction Therapy for High Risk Neuroblastoma
Neuroblastoma
Primary: Response Rate Associated With Two Cycles of Cisplatin With Protracted Oral Etoposide When Administered as Up-front Window Therapy to Previously Untreated Children With…
Phase 2 N=16 Eurosarc Trial of Linsitinib in Advanced Ewing Sarcoma
Relapsed Ewing Sarcoma · Refractory Ewing Sarcoma
Primary: Number of Participants With a Metabolic Response as Evaluated by PERCIST v1.0 — 1; 2; 4; 3 Participants
N/A N=545 Patterns of Care and Outcomes in Patients With Metastatic Bone Tumors (METABONE)
Metastatic Bone Tumor
Primary: Overall Survival (OS) — 21.5; 12.7; 26.6 months
Phase 3 N=109 High-Dose Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Metastatic Rhabdomyosarcoma or Ectomesenchymoma
Sarcoma
Primary: Number of Patients With Complete or Partial Response Assessed by RECIST Criteria — 63 percentage of participants
Phase 2 N=22 A Two-part Phase IIb Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Ewing's Sarcoma
Ewing's Sarcoma
Primary: Number of Participants With Adverse Events Determined by Laboratory Assessments and Physical Examinations — 5; 6; 9 Participants
Phase 2 N=25 SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors
Malignant Peripheral Nerve Sheath Tumors · MPNST · Sarcoma
Primary: Clinical Benefit Rate (Complete Response, Partial Response, and Stable Disease at ≥ 4 Months Using World Health Organization (WHO) Criteria) of Everolimus in Combination…
Phase 1 N=50 A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma
Neoplasms
Primary: Objective Response Rate (ORR) — 50; 30.8; 20; 26.7 Percentage of Participants